A Phase 2a clinical trial testing the oral cannabidiol-derived medication EHP-101 in people with diffuse cutaneous systemic sclerosis can proceed…
Articles by Patricia Inácio, PhD
A 42-year-old man with scleroderma responded well to a second stem cell transplant after experiencing a disease relapse with…
In a real-world study, the systemic sclerosis (SSc) medication RoActemra (tocilizumab) failed to significantly lessen skin and lung scarring…
The release of CXCL10 — an inflammatory signaling molecule associated with a worse prognosis in scleroderma — from connective tissue…
Being male is linked with a higher risk of mortality among patients with scleroderma, irrespective of the type of…
The levels of certain metabolites — molecules that take part in metabolism — circulating in the blood may help differentiate…
Between 4% and 6% of people with scleroderma (SSc) were first determined to have an interstitial lung disease (ILD),…
A total of 30 patient advocacy groups working to further understanding and the needs of people living with rare diseases…
The immunosuppressant rituximab may help stabilize lung function in people with systemic sclerosis-related interstitial lung disease (SSc-ILD), a study…
Daily oral treatment with zibotentan, a blocker of the endothelin protein receptor, was found safe, and possibly may be able…